Inspired Spine, a leading innovator in medical spine technology, in partnership with Avicenna Technical University, is proud to announce the creation of SURI (Smart Universal Resource Identifier), an advanced, AI-based medical record system designed to revolutionize medical informatics....
Read more
Aviva Aesthetics is proud to announce its latest partnership with iAesthetic Medspa, a premier medical aesthetics practice in Erie, Pennsylvania, led by Dr. Sarah Carter. This partnership marks Aviva's continued growth in the Midwest, reinforcing its commitment to excellence in aesthetics while enabling industry-leading providers to prioritize their patients over administrative responsibilities.Dr. Carter, a key opinion leader in the industry...
Read more
The field of cosmetic medicine is evolving at an unprecedented pace, with non-invasive procedures becoming the gold standard for individuals seeking aesthetic improvements without the risks and downtime of traditional surgery. An exclusive online article, The Future of Non-Invasive Cosmetic Procedures: How Technology is Reshaping Aesthetic Medicine, explores this trend and features insights from Dr. Ammar Mahmoud, a leading cosmetic...
Read moreMARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is pleased to announce it has received a response from the FDA regarding its Orphan Drug application filed last year under Exousia AI for its Glioblastoma treatment using exosomes.The FDA has been very responsive in its emails and phone calls and has requested additional information that is...
Read more
Gubra (CPH:GUBRA):With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, all closing conditions of the license agreement have today been satisfied and the license agreement has become effective.Contacts at Gubra:Media: Sofia Pitt Boserup,...
Read more
Serve You Rx, a full-service pharmacy benefit manager (PBM), today announced a strategic partnership with Waltz Health to integrate Waltz Connect, an AI-powered specialty platform. This enhancement allows Serve You Rx to address rapidly growing specialty medication costs, which have increased by more than 40% in just a few years to $300 billion annually.By integrating Waltz Connect, Serve You Rx continues its tradition of unquestionable...
Read more
Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL's new go-to-market strategy is for the...
Read more
Sjögren's disease is a serious, systemic autoimmune disease that affects millions of people, yet it remains widely misunderstood and underdiagnosed. While commonly known for causing dry eyes and dry mouth, Sjögren's is a complex disease that impacts the entire body and causes chronic pain, severe fatigue, and neurological symptoms. Additional complications can include damage to kidneys, lungs, liver, and the heart. Sjögren's can also lead to...
Read more
CADIS HealthTech, a health technology startup developing cutting-edge smart technology to expand global healthcare access and physician availability, has launched EziExpert ("easy expert") Enhanced Telehealth and Remote Consultation Platform with augmented reality (AR) and AI. This first-of-its-kind system connects a remotely located physician to any healthcare assistant/nurse wearing AR smart glasses caring for the patient, while simultaneously...
Read more
CenExel, a leading clinical research site network, has launched a new mobile application designed to make it easier for patients to find and participate in clinical trials. Now available on both the Apple App Store and Google Play Store, the CenExel Patient Recruitment App streamlines the search process for studies that match individual interests and eligibility criteria.The new app empowers patients by providing a user-friendly interface to...
Read more
In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years into his virology research career at Gilead and the first daily single tablet regimen for HIV treatment was still awaiting approval. Treatment options for people living with HIV at the time were a raft of daily medications that often carried...
Read more
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the full year ended December 31, 2024 and outlined recent corporate and clinical development highlights."Oncology drug development can be complex and challenging, but the GBM patients...
Read more
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of the first subjects in its Phase 1 clinical trial of Ketamir-2, a novel oral ketamine analog in development for the treatment of neuropathic pain.The Phase 1 trial is being conducted at the Clinical Pharmacology Unit of Hadassah Medical Center in...
Read more
Germany's Electronic Health Record (EHR) sector is entering a critical period of transformation, according to new survey findings released by Black Book Research. Feedback collected from 410 German hospital executives, health IT administrators, and physician organization stakeholders between Q3 2024 and Q1 2025 reveals a nationwide shift toward infrastructure modernization, patient-centric data models, and interoperability readiness.Fragmented...
Read moreAcuity Behavioral Health (Acuity) today announced its official launch, pioneering a new category in healthcare: Behavioral Health Operations Intelligence (BHOI). Built in collaboration with 11 leading health systems, including Yale New Haven Health, Acuity's platform provides a real-time, AI-driven framework for standardizing, measuring, and optimizing inpatient psychiatric care-a field long plagued by inefficiencies, staffing shortages, and a...
Read more
CBD Life Sciences Inc. (OTC PINK:CBDL) is making bold strides into the booming functional mushroom sector, positioning itself at the forefront of a revolution that is reshaping cognitive health and wellness. As the demand for natural, scientifically backed solutions grows, CBDL's strategic expansion into brain-boosting mushroom applications signals a major step forward in harnessing the power of nature to optimize mental performance, longevity,...
Read more
Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief Medical Officer, effective immediately."I am extremely pleased that Morten has decided to join Cantargia. He brings experience and expertise within the development of treatments for autoimmune and inflammatory diseases that are critical for our continued journey, not the least with the CAN10...
Read more
In a twist that even the most jaded D.C. insiders are calling "poetic justice," cannabis research giant MMJ International Holdings, MMJ BioPharma Cultivation and MMJ BioPharma Labs has delivered an April Fools' Day gut-punch to the Drug Enforcement Administration (DEA). Fresh off the DOJ's stunning admission that the DEA's administrative law judge (ALJ) system is unconstitutional, MMJ filed a suit for irreparable "unconstitutional harm" today,...
Read more
AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company is participating at Redeye Theme: Alzheimer & Parkinsons on April 8, 10:55am, when CEO Martin Jönsson presents the company and its pipeline within Alzheimer's.Watch the livestream via...
Read more
Senzime (STO:SEZI)(OTCQX:SNZZF) - The number of shares and votes in Senzime has increased during the month of March due to the directed issue of shares resolved by the board on February 26, 2025, as authorized by the general meeting on May 16, 2024.As of March 31, 2025, the total number of shares in Senzime amounts to 133,215,046 (previously 133,174,523 shares), with one vote each. The share capital amounts to SEK 16,651,880.75 (previously SEK...
Read more
